AMFR
AMFR (autocrine motility factor receptor, also known as gp78 and RNF45) is an endoplasmic reticulum membrane E3 ubiquitin-protein ligase. It drives ER-associated degradation of specific substrates and also acts as the receptor for autocrine motility factor. Browse Assay Genie's current range of AMFR research reagents below, or read on for the biology behind the target.
AMFR is an E3 ubiquitin-protein ligase that mediates polyubiquitination of target proteins for proteasomal degradation. Substrates named in the annotation include CD3D, CYP3A4, CFTR, INSIG1, SOAT2/ACAT2 and APOB. Unusually, it modifies cysteine as well as lysine residues: together with INSIG1 it polyubiquitinates SOAT2/ACAT2 at Cys-277 when lipid levels are low, and it ubiquitinates INSIG2 at Cys-215 in some tissues.
AMFR is a component of a VCP/p97-AMFR/gp78 complex that acts in the final step of endoplasmic reticulum-associated degradation (ERAD). This complex binds the HMGCR-INSIG1 complex at the ER membrane and promotes sterol-accelerated degradation of HMGCR. Interaction of AMFR with AUP1 helps recruit the ubiquitin-conjugating enzyme UBE2G2 and the ubiquitin ligase RNF139, leading to sterol-induced HMGCR ubiquitination, after which the ubiquitinated HMGCR is released from the ER into the cytosol. AMFR also ubiquitinates UBL4A, a component of the BAG6/BAT3 complex, and serves as a scaffold that couples ubiquitination, retranslocation and deglycosylation. It is required for proper lipid homeostasis.
Beyond ERAD, AMFR regulates signalling. With LMBR1L and UBAC2 it negatively regulates canonical Wnt signalling in lymphocytes by promoting degradation of CTNNB1 and the Wnt receptors FZD6 and LRP6. It also regulates NF-kappa-B and MAPK signalling through Lys-27-linked polyubiquitination of TAB3, which promotes TAK1/MAP3K7 activation. The AMFR gene encodes a glycosylated transmembrane receptor for autocrine motility factor, a motility-stimulating protein secreted by tumour cells, and the protein mediates tumour invasion and metastasis. HGNC places it among RING finger E3 ubiquitin protein ligases that contain a CUE domain.
AMFR is part of the VCP/p97-AMFR/gp78 complex acting in the final step of ERAD, making it a model for studying substrate retrotranslocation and degradation.
AMFR drives sterol-regulated degradation of HMGCR, INSIG1 and SOAT2/ACAT2, and is required for proper lipid homeostasis.
As the receptor for autocrine motility factor, AMFR mediates tumour invasion and metastasis, linking it to cancer cell motility research.
AMFR promotes degradation of CTNNB1, FZD6 and LRP6 and ubiquitinates TAB3 to activate TAK1, connecting ubiquitination to signalling control.
AMFR is an ER membrane E3 ubiquitin ligase that polyubiquitinates substrates such as INSIG1, HMGCR-associated complexes, CFTR and APOB for proteasomal degradation during ERAD. It also acts as the receptor for autocrine motility factor and regulates Wnt, NF-kappa-B and MAPK signalling.
gp78 and RNF45 are alternative names for the same protein. The HGNC symbol AMFR reflects its role as the autocrine motility factor receptor, while RNF45 reflects its RING finger domain and E3 ligase activity. The UniProt entry is named E3 ubiquitin-protein ligase AMFR.
A mouse ortholog, Amfr, is recorded for this gene. The annotation links AMFR to tumour invasion and metastasis through its role as the autocrine motility factor receptor. Check the datasheet of any product for its validated reactivity.
Substrates, ERAD partners and signalling proteins linked to AMFR, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9UKV5; product specifications from Assay Genie datasheets.